These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3872772)

  • 1. Determinations of cerebral glucose utilization in dementia using positron emission tomography.
    Kuhl DE; Metter EJ; Riege WH; Hawkins RA
    Dan Med Bull; 1985 Feb; 32 Suppl 1():51-5. PubMed ID: 3872772
    [No Abstract]   [Full Text] [Related]  

  • 2. 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia.
    Farkas T; Ferris SH; Wolf AP; De Leon MJ; Christman DR; Reisberg B; Alavi A; Fowler JS; George AE; Reivich M
    Am J Psychiatry; 1982 Mar; 139(3):352-3. PubMed ID: 6977276
    [No Abstract]   [Full Text] [Related]  

  • 3. Positron emission tomography as an imaging tool in psychiatric disorders.
    Heiss WD; Pawlik G; Herholz K; Szelies B; Wienhard K
    Psychiatry Res; 1989 Sep; 29(3):351-2. PubMed ID: 2532752
    [No Abstract]   [Full Text] [Related]  

  • 4. [Functional significance of calcinosis of the basal ganglia via positron emission tomography].
    Staffen W; Karbe H; Rudolf J; Herholz K; Diederich N; Heiss WD
    Fortschr Neurol Psychiatr; 1994 Apr; 62(4):119-24. PubMed ID: 8206464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional imaging in dementia: an overview.
    Jagust WJ
    J Clin Psychiatry; 1994 Nov; 55 Suppl():5-11. PubMed ID: 7989292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
    Weinberger DR; Jones D; Reba RC; Mann U; Coppola R; Gibson R; Gorey J; Braun A; Chase TN
    J Neuropsychiatry Clin Neurosci; 1992; 4(3):239-48. PubMed ID: 1498576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of cerebral glucose utilization in dementia.
    Matsuzawa T; Matsui H; Meguro K; Ueda M; Yamada K; Yamaguchi T; Itoh M; Hatazawa J; Kinomura S
    Sci Rep Res Inst Tohoku Univ Med; 1990 Dec; 37(1-4):11-21. PubMed ID: 2103655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical stages in subjects at risk for neurological disorders: can PET-FDG tell us more?
    Azari NP; Pietrini P
    J Neurol; 1995 Jan; 242(2):112-4. PubMed ID: 7707087
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in glucose metabolism in dementia of the Alzheimer type compared with depression: a preliminary report.
    Guze BH; Baxter LR; Schwartz JM; Szuba MP; Mazziotta JC; Phelps ME
    Psychiatry Res; 1991 Nov; 40(3):195-202. PubMed ID: 1780392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomographic studies of aging and Alzheimer disease.
    de Leon MJ; Ferris SH; George AE; Christman DR; Fowler JS; Gentes C; Reisberg B; Gee B; Emmerich M; Yonekura Y; Brodie J; Kricheff II; Wolf AP
    AJNR Am J Neuroradiol; 1983; 4(3):568-71. PubMed ID: 6410799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain glucose metabolism in Parkinson's disease.
    Metter EJ; Kuhl DE; Riege WH
    Adv Neurol; 1990; 53():135-9. PubMed ID: 2239454
    [No Abstract]   [Full Text] [Related]  

  • 12. Alzheimer's dementia.
    Chase TN; Tamminga CA
    Am J Psychiatry; 1995 Aug; 152(8):1110. PubMed ID: 7625456
    [No Abstract]   [Full Text] [Related]  

  • 13. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose.
    Friedland RP; Budinger TF; Ganz E; Yano Y; Mathis CA; Koss B; Ober BA; Huesman RH; Derenzo SE
    J Comput Assist Tomogr; 1983 Aug; 7(4):590-8. PubMed ID: 6602819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET and differential diagnosis of dementia.
    Herholz K
    Alzheimer Dis Assoc Disord; 1995; 9(1):6-16. PubMed ID: 7605624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography in dementia.
    Friedland RP
    Semin Neurol; 1989 Dec; 9(4):338-44. PubMed ID: 2701778
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron emission tomography with [18F]fluorodeoxyglucose differentiates normal pressure hydrocephalus from Alzheimer-type dementia.
    Jagust WJ; Friedland RP; Budinger TF
    J Neurol Neurosurg Psychiatry; 1985 Nov; 48(11):1091-6. PubMed ID: 3878390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET: studies in dementia.
    Frackowiak RS
    Psychiatry Res; 1989 Sep; 29(3):353-5. PubMed ID: 2692056
    [No Abstract]   [Full Text] [Related]  

  • 18. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia.
    Benson DF; Kuhl DE; Hawkins RA; Phelps ME; Cummings JL; Tsai SY
    Arch Neurol; 1983 Nov; 40(12):711-4. PubMed ID: 6605139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of cerebral glucose utilization in depression, multiple infarct dementia, and Alzheimer's disease.
    Kuhl DE; Metter EJ; Riege WH
    Res Publ Assoc Res Nerv Ment Dis; 1985; 63():211-26. PubMed ID: 4023401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional cerebral glucose utilization in chronic organic mental disorders associated with alcoholism.
    Martin PR; Rio D; Adinoff B; Johnson JL; Bisserbe JC; Rawlings RR; Rohrbaugh JW; Stapleton JM; Eckardt MJ
    J Neuropsychiatry Clin Neurosci; 1992; 4(2):159-67. PubMed ID: 1627977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.